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The p53 pathway is an intrinsic monitor and response
pathway of telomeric attrition involved in cellular aging
and senescence. Cellular senescence is tumor suppres-
sive that can be activated by p53 in cancer cells. We are
studying the molecular mechanisms of cellular senes-
cence in normal and malignant human cells and the
role of the telometric multiprotein complex, shelterin,
that includes TRF2 and POT1 [1-3]. Our ongoing stu-
dies have revealed that p53 and its endogenous isoforms
regulate both specific microRNAs and TRF2 expression
as mechanisms of replicative senescence. In addition,
POT1 isoforms are functionally diverse in both main-
taining telomeric integrity and preventing p53-
dependent senescence induced by telomeric shortening.
A switch in the expression patterns of p53 isoforms,
Δ133Np53 and p53 beta, is also associated with the
transition of benign to malignant human cancers.
Chronic inflammation and deregulation of microRNAs
have roles in human carcinogenesis [4-7]. In addition to
our mechanistic and genetic studies, we are investigating
the expression of microRNAs and inflammatory genes
as cancer biomarkers of diagnosis, prognosis, and thera-
peutic outcome [8-11]. We are especially interested in
developing prognostic classifiers of early stage cancer.
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